Safety of aerosolized amphotericin B lipid complex in lung transplant recipients.
about
Critical care aspects of lung transplantation.Aspergillus infections in transplant recipients.A phospholipid-apolipoprotein A-I nanoparticle containing amphotericin B as a drug delivery platform with cell membrane protective propertiesPractice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Antifungal pharmacotherapy for invasive mould infections.Amphotericin B lipid complex for the treatment of invasive fungal infections.New and emerging antifungal agents: impact on respiratory infections.Novel modes of antifungal drug administration.Inhaled therapeutics for prevention and treatment of pneumoniaAerosolised antibiotics: a critical appraisal of their use.Fungal infections in solid organ transplantation.Significance of and risk factors for the development of central airway stenosis after lung transplantation.Critical care perspective on immunotherapy in lung transplantation.Strategies for the prevention of infection after solid organ transplantation.Invasive fungal infections and antifungal therapies in solid organ transplant recipients.Safety of aerosolized amphotericin B.Diagnosis and outcome of early pleural space infection following lung transplantation.Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?Aerosolized amphotericin B lipid complex as adjunctive treatment for fungal lung infection in patients with cancer-related immunosuppression and recipients of hematopoietic stem cell transplantation.Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients.Prophylactic antifungal agents used after lung transplantation.Lung transplant infection.Anti-Aspergillus Prophylaxis in Lung Transplantation: A Systematic Review and Meta-analysis.Is universal antifungal prophylaxis mandatory in adults after lung transplantation? A review and meta-analysis of observational studies.Monitoring safety of liposomes containing rifampicin on respiratory cell lines and in vitro efficacy against Mycobacterium bovis in alveolar macrophages.Fungal Infections After Lung Transplantation.Prophylactic application of nebulized liposomal amphotericin B in hematologic patients with neutropenia.Aerosolized Delivery of Antifungal AgentsAspergillosis in solid organ transplantation.Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis.New agents for the treatment of systemic fungal infections--current status.Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients.Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study
P2860
Q33360317-B1CF7C86-D8C5-4251-BF5B-E14721E021FBQ33719294-BF34EB61-50B0-4D08-B509-E820EA2F9158Q34160941-6AD2F9A9-2B7E-4973-868A-0E973B2E1852Q34532546-63D724D3-8743-44F7-AB91-3C118F3EC9CDQ35058091-F0388CD2-F589-4D32-B408-F10759D2CE29Q35575017-3ABD89CD-723B-432E-8F90-11FD3C1E6C9EQ35627629-43A128D1-9009-41C9-A87D-3464BBC4E41AQ35842520-8E9344E4-BB29-4EA4-94CA-7DFC65ADDCF7Q35925366-76968C58-6DA5-462F-862F-F49F39DE319EQ36349691-A2A7265B-7035-4491-8406-7C61BC7A69F8Q36382578-B88FA513-B4F0-47D0-9C23-1E986D10B36EQ36572613-3188134D-1D84-44F4-B6F7-A5FDCABA834EQ36649380-984FB16B-EA07-46AA-B013-78B2FAA14F59Q36670902-AE76C4AA-B2D8-4DD4-A1F5-C00E79BF9E75Q36872848-84419BC7-4F06-4305-AA18-4B03F3E845BDQ36945011-786AE79F-2181-4E6B-A575-CBD2E5845D91Q37066044-C0851888-2182-49F2-9110-8CDFCEF8669CQ37098160-2999FEF3-458E-4D5C-87A3-812BE46D2026Q37216741-296CAC7F-05E5-4A0E-927C-4055AF1E7219Q37650317-349214D1-67B0-4494-BB03-0051859F2A69Q37697380-C7DDA089-57C7-488B-AFFC-8B33EB18D7C9Q38010486-0871F795-B9FB-4FCE-B029-11B897535976Q38156666-98C9AAAD-ABD2-4A88-8350-CF90DAE8874CQ38960760-983B049F-9B24-4E47-8C15-D5DFB6742815Q39782529-09E8E544-E5A7-44A3-B73A-C70C3EAE0388Q40098248-96BB2E87-D931-4438-AC2F-FEBD3F3EB34DQ40324756-0F495C1E-1FB0-4057-B7FA-A279B5C87EF3Q40522508-0DB75F75-3803-4B49-96EE-291625BA88A1Q42272291-A41EA03B-73B8-440B-8F34-599DDB0BF785Q45018397-8F16251E-DCA0-4756-8B4D-E0C6F4C8B337Q46576615-8C0264BD-2B36-4453-A52F-03FFCBC38C8BQ51116991-8A2DC609-79A0-41F7-B4AB-C2B8C5160FC4Q53626853-A63535EC-8853-4FE5-AA30-99E30576B8A0Q57053359-0EF0F3DB-0049-421B-96B7-91F7518F3249
P2860
Safety of aerosolized amphotericin B lipid complex in lung transplant recipients.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Safety of aerosolized amphotericin B lipid complex in lung transplant recipients.
@en
Safety of aerosolized amphotericin B lipid complex in lung transplant recipients.
@nl
type
label
Safety of aerosolized amphotericin B lipid complex in lung transplant recipients.
@en
Safety of aerosolized amphotericin B lipid complex in lung transplant recipients.
@nl
prefLabel
Safety of aerosolized amphotericin B lipid complex in lung transplant recipients.
@en
Safety of aerosolized amphotericin B lipid complex in lung transplant recipients.
@nl
P2093
P1433
P1476
Safety of aerosolized amphotericin B lipid complex in lung transplant recipients.
@en
P2093
McConnell RR
Perfect JR
Whitehouse JD
P304
P356
10.1097/00007890-200108150-00036
P577
2001-08-01T00:00:00Z